» Articles » PMID: 30586485

Adalimumab Persistence for Inflammatory Bowel Disease in Veteran and Insured Cohorts

Overview
Journal Am J Manag Care
Specialty Health Services
Date 2018 Dec 27
PMID 30586485
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Identify predictors of persistence with adalimumab (ADA) among veterans and privately insured patients with inflammatory bowel disease (IBD) in the United States.

Study Design: Retrospective cohort study.

Methods: Patients with IBD taking ADA as their first biologic were identified from the Veterans Health Administration (VHA) database from 2009 to 2013 and the Truven Health MarketScan database from 2009 to 2012 with a 12-month follow-up. Persistence was defined as continued use 1 year after initiation. Adherence was assessed by calculating a medication possession ratio, which was dichotomized as greater than 0.86 or less than or equal to 0.86. Multivariable logistic regression was used to evaluate predictors of persistence.

Results: There were 1030 patients in the VHA population compared with 3264 patients in the privately insured (MarketScan) cohort. In MarketScan, 1800 patients (55%) remained on ADA compared with 755 (73%) in the VHA cohort. In multivariable analysis, male sex (odds ratio [OR], 1.38; 95% CI, 1.16-1.63; P <.01), Crohn disease (OR, 1.27; 95% CI, 1.02-1.57; P = .03), greater adherence (OR, 1.83; 95% CI, 1.45-2.30; P <.01), and dose escalation (OR, 1.82; 95% CI, 1.42-2.33; P <.01) were associated with higher ADA persistence in the MarketScan cohort; narcotic use (OR, 0.71; 95% CI, 0.58-0.88; P <.01) and hospitalization or new steroid use after initiation (OR, 0.04; 95% CI, 0.03-0.05; P <.01) were associated with lower persistence. In the VHA cohort, only a hospitalization or new steroid use (OR, 0.50; 95% CI, 0.36-0.70; P <.01) was associated with lower persistence.

Conclusions: Despite being older and having more comorbidities, patients in the VHA, which is an integrated healthcare system, appear to be more likely to remain on ADA at 1 year than patients in the MarketScan database. Further studies of system differences are needed to understand the reasons behind this discrepancy.

Citing Articles

Worse outcomes and higher costs of care in fibrostenotic Crohn's disease: a real-world propensity-matched analysis in the USA.

Dehghan M, Wong G, Neuberger E, Kin C, Rieder F, Park K BMJ Open Gastroenterol. 2021; 8(1).

PMID: 34930755 PMC: 8689124. DOI: 10.1136/bmjgast-2021-000781.


Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn's Disease Patients with Prescription Claims for Ustekinumab in the USA.

Ding Z, Obando C, Muser E, Kozma C, Slaton T Drugs Real World Outcomes. 2021; 8(4):565-575.

PMID: 34136998 PMC: 8605940. DOI: 10.1007/s40801-021-00264-5.


Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.

Curtis J, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N Inflamm Bowel Dis. 2020; 27(9):1394-1408.

PMID: 33324993 PMC: 8376127. DOI: 10.1093/ibd/izaa289.


Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis.

Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T J Gastroenterol Hepatol. 2019; 35(2):225-232.

PMID: 31397010 PMC: 7027773. DOI: 10.1111/jgh.14825.

References
1.
Asch S, McGlynn E, Hogan M, Hayward R, Shekelle P, Rubenstein L . Comparison of quality of care for patients in the Veterans Health Administration and patients in a national sample. Ann Intern Med. 2004; 141(12):938-45. DOI: 10.7326/0003-4819-141-12-200412210-00010. View

2.
Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer S, Panaccione R . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132(1):52-65. DOI: 10.1053/j.gastro.2006.11.041. View

3.
Limsrivilai J, Stidham R, Govani S, Waljee A, Huang W, Higgins P . Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2016; 15(3):385-392.e2. PMC: 5503504. DOI: 10.1016/j.cgh.2016.09.012. View

4.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

5.
Feagins L, Waljee A, Hou J, Gu P, Kanjo S, Rudrapatna V . Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017; 23(8):1434-1439. DOI: 10.1097/MIB.0000000000001145. View